Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks 50 Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Ratings
Abivax’s Obefazimod: A Promising Contender in Ulcerative Colitis Treatment with Potential Market Impact
1d ago
ABVX
Premium
Ratings
Positive Outlook for Abivax SA: Anticipated Success of Obefazimod in Ulcerative Colitis Treatment
4d ago
ABVX
Premium
Ratings
Buy Rating Justified for Abivax SA: Promising Efficacy of Obefazimod in Ulcerative Colitis and Crohn’s Disease
13d ago
ABVX
Premium
Ratings
Abivax’s Potential in IBD Market: Buy Rating Backed by Phase 3 Trials and Industry Trends
25d ago
ABVX
Premium
Ratings
Promising Outlook for Abivax’s Obefazimod in Ulcerative Colitis with Upcoming Phase 3 Results as Key Catalyst
1M ago
ABVX
Premium
Pre-Earnings
0RA9 Upcoming Earnings Report: What to Expect?
1M ago
Premium
Ratings
Optimistic Buy Rating for Abivax SA: Obefazimod’s Potential in Ulcerative Colitis and Market Opportunity
2M ago
ABVX
Premium
Ratings
Promising Potential of Abivax SA’s Obefazimod in Ulcerative Colitis Drives Buy Rating
2M ago
ABVX
Premium
Ratings
Optimistic Buy Rating for Abivax SA Driven by Promising Phase 3 Developments and Market Potential
2M ago
ABVX
Premium
The Fly
Abivax completes enrollment in ABTECT trials
2M ago
ABVX
Premium
The Fly
Abivax management to meet with BTIG
2M ago
ABVX
Premium
Company Announcements
Abivax Announces Share and Voting Rights Update
3M ago
Premium
Ratings
Abivax SA: Promising Clinical Developments and Positive Outlook Justify Buy Rating
3M ago
ABVX
Premium
Company Announcements
Abivax Files Key Financial Documents with Regulatory Authorities
3M ago
Premium
Ratings
Promising Prospects for Abivax: Buy Rating Backed by Clinical Progress and Financial Strength
3M ago
ABVX
Premium
Ratings
Abivax SA’s Obefazimod: A Promising Blockbuster in Ulcerative Colitis Treatment
3M ago
ABVX
Premium
Ratings
Positive Outlook for Abivax: Buy Rating Supported by Promising Phase 3 Trials and Strong Financial Position
4M ago
ABVX
Premium
Company Announcements
Abivax SA Reports 2024 Financial Results and Advances Phase 3 Trials
4M ago
Premium
Pre-Earnings
0RA9 Earnings this Week: How Will it Perform?
4M ago
Premium
The Fly
Abivax assumed with an Equal Weight at Morgan Stanley
4M ago
ABVX
Premium
Ratings
Buy Rating for Abivax SA Driven by Promising Obefazimod Data and Market Potential
4M ago
ABVX
Premium
Ratings
Abivax’s Obefazimod: A Promising New Treatment for Ulcerative Colitis with Phase 3 Data Anticipated in 2025
4M ago
ABVX
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
